This review discusses the clinical evidence on FLT3-specific tyrosine kinase inhibitors (TKIs) being used as post-transplant maintenance in patients with FLT3-ITD acute myelogenous leukemia (AML) who are at high-risk for disease relapse. The authors report results from preliminary studies and case reports of FLT3 TKIs currently being evaluated in clinical studies, and note that early results indicate that post-transplant FLT3 TKI therapy is well-tolerated and may be effective in improving outcomes in patients.
- AML in Adults: Transplant Indications and Outcomes
- Education Course: AML and MDS in Older Patients
- Education Course: AML Treatment Options, including BMT, Care and Support (for Hem/Onc BMT nurses and other BMT health care professionals)